Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :215
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1133    
    Printed21    
    Emailed0    
    PDF Downloaded207    
    Comments [Add]    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2015  |  Volume : 52  |  Issue : 3  |  Page : 305-307

Hematologic, liver enzymes and electrolytes changes in chronic myeloid leukemia after Imatinib medication


1 Department of Internal Medicine, Arak University of Medical Sciences, Arak, Iran
2 Department of Hematology and Oncology, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Cardiac Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
5 Department of Epidemiology and Biostatistics, Health Policy and Promotion Research Center, Qom University of Medical Sciences, Qom, Iran

Correspondence Address:
A Mohammadbeigi
Department of Epidemiology and Biostatistics, Health Policy and Promotion Research Center, Qom University of Medical Sciences, Qom
Iran
Login to access the Email id

Source of Support: Arak University of Medical Sciences, Arak, Iran, Conflict of Interest: None


DOI: 10.4103/0019-509X.176715

Rights and Permissions

Background: Chronic myeloid leukemia (CML), is the first malignancy that related to the chromosomal abnormality and include 15-20% of all adulthood leukemia. AIMS: This study aimed to compare the hematologic, breakpoint cluster region-abelson (BCR-ABL) and liver function enzymes changes during treatment period of Imatinib. Settings And Design: A noncurrent clinical trial study. Materials And Methods: New incident CML patients received Iranian made or Indian-made Imatinib after baseline measurement. Hematologic, BCR-ABL, electrolytes and liver function enzymes measured again after 24 weeks. Statistical Analysis Used: Paired t-test and independent t-test was used to assess the effect of treatment in within and between groups, respectively. Results: Imatinib has a decreasing impact on white blood cells and placates. While an increasing effect on hemoglobin concentration. Iranian made and Indian-made Imatinib has a same effect on improvement of hematologic, BCR-ABL, electrolytes in CML patients. However, the liver changes of Imatinib were not clinically significant. Conclusion: The Iranian-made Imatinib can be used as a replacement for Indian made ones without any statistical and clinical significant difference on Improvement of CML patients.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow